572P Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intrapatient heterogeneity in ER+/HER2- metastatic breast cancer (MBC) treated with first-line endocrine therapy: Final results of the ET-FES trial. - Gennari, A.; Nardin, S.; Brain, E.G.C.; Piccardo, A.; De Censi, A.; Matteucci, F.; Wuerstlein, R.; Seban, R.; Fiz, F.; Ruffilli, B.; Bottoni, G.; Sacchetti, G.M.; et al. (Annals of Oncology, 2025)